Literature DB >> 7640474

A 10-year survivor with unresectable hepatic metastases from sigmoid colon carcinoma treated with regional chemotherapy.

S Takeda1, K Hisatomi, S Nakano, K Okamoto, Y Nagafuchi, H Itoh, K Ohsato.   

Abstract

We treated a man with unresectable hepatic metastases from sigmoid colon carcinoma who has since survived for more than 10 years. A sigmoidectomy with lymph node dissection was performed and a continuous hepatic arterial infusion of 5-fluorouracil (5-FU) with intermittent infusion of mitomycin C (MMC) was administered for about 3 months after this operation. The total doses of 5-FU and MMC were 16 g and 84 mg, respectively. Tegafur also was administered orally at a dose of 600 mg/day for about 8 months. The carcinoembryonic antigen (CEA) level (which had reached 4,409 ng/ml preoperatively) normalized 4 months after surgery, and still remains normal. Very few patients with unresectable hepatic metastases survive for 5 or more years. However, regional chemotherapy can be effective in some patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7640474     DOI: 10.1007/bf00311823

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  25 in total

1.  THE RATIONALE OF PALLIATIVE RESECTION FOR PRIMARY CANCER OF THE COLON AND RECTUM COMPLICATED BY LIVER AND LUNG METASTASIS.

Authors:  H E BACON; P V MARTIN
Journal:  Dis Colon Rectum       Date:  1964 May-Jun       Impact factor: 4.585

2.  Prognosis of carcinoma of the large bowel in the presence of liver metastases.

Authors:  E M Oxley; H Ellis
Journal:  Br J Surg       Date:  1969-02       Impact factor: 6.939

3.  Survival of patients after colonic resection for carcinoma with simultaneous liver metastases.

Authors:  B Cady; D O Monson; N W Swinton
Journal:  Surg Gynecol Obstet       Date:  1970-10

4.  Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal cancer.

Authors:  H J Staab; F A Anderer; E Stumpf; R Fischer
Journal:  Am J Surg       Date:  1978-09       Impact factor: 2.565

5.  Survival of patients with untreated liver metastases from colorectal cancer.

Authors:  H Baden; B Andersen
Journal:  Scand J Gastroenterol       Date:  1975       Impact factor: 2.423

6.  Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver.

Authors:  M J O'Connell; M A Adson; A J Schutt; J Rubin; C G Moertel; D M Ilstrup
Journal:  Mayo Clin Proc       Date:  1985-08       Impact factor: 7.616

7.  A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma.

Authors:  C J Lahr; S J Soong; G Cloud; J W Smith; M M Urist; C M Balch
Journal:  J Clin Oncol       Date:  1983-11       Impact factor: 44.544

8.  Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries.

Authors:  M M Kemeny; D Goldberg; J D Beatty; D Blayney; S Browning; J Doroshow; L Ganteaume; R L Hill; W A Kokal; D U Riihimaki
Journal:  Cancer       Date:  1986-02-01       Impact factor: 6.860

9.  Long-term survivors of colorectal cancer with unresectable hepatic metastases.

Authors:  S Fujimoto; M Miyazaki; Y Kitsukawa; M Higuchi; K Okui
Journal:  Dis Colon Rectum       Date:  1985-08       Impact factor: 4.585

10.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.

Authors:  P GOLD; S O FREEDMAN
Journal:  J Exp Med       Date:  1965-03-01       Impact factor: 14.307

View more
  1 in total

1.  Monitoring carcinoembryonic antigen in colorectal cancer: is it still useful?

Authors:  G Li Destri; S Greco; C Rinzivillo; A Racalbuto; R Curreri; A Di Cataldo
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.